###begin article-title 0
###xml 89 97 <span type="species:ncbi:9606">Patients</span>
Analysis of the Monocyte Chemoattractant Protein 1 -2518 Promoter Polymorphism in Korean Patients with Alopecia Areata
###end article-title 0
###begin p 1
###xml 1081 1082 1081 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1090 1091 1090 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1201 1206 1201 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
###xml 1054 1062 <span type="species:ncbi:9606">patients</span>
Monocyte chemoattractant protein-1 (MCP-1) levels are increased in scalp lesions of patients with alopecia areata (AA), suggesting a role in the development of AA. Recently, a biallelic A/G polymorphism in the MCP-1 promoter at position -2518 has been found, influencing the level of MCP-1 expression in response to an inflammatory stimulus. We investigated whether the presence of these polymorphisms were associated with AA in Korean population. 145 Korean patients with AA, 246 healthy subjects without clinical evidence of AA were screened for genotype with a PCR-based assay. In the AA patients the frequency of the A and G alleles was 40.3 and 59.7%, respectively and the distribution of the A/A, A/G and G/G genotypes was 19.3, 42.1 and 38.6%, respectively. Amongst the controls the frequency of the A and G alleles was 39.8 and 60.2%, and the distribution of the A/A, A/G, G/G genotypes in the same group was 17.5, 44.7 and 37.8%, respectively. There was no significant difference in the allele frequencies and genotype distributions between the patients and the controls (p=0.889, p=0.848, respectively). Our data indicates that no association exists between the -2518A/G polymorphism of the MCP-1 gene and susceptibility to alopecia areata.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 279 280 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 580 581 580 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
Alopecia areata (AA) is a disfiguring disease characterized by nonscarring hair loss. It is a chronic inflammatory disorder affecting both the hair follicles and the nail apparatus, with T-lymphocyte infiltration and chemokine expression being characteristic in involved tissue (1). The prevalence rates of AA is 0.1% in the world population (2) and 0.9-6.9% in Korea (3). The association of AA with autoimmune diseases including thyroid disorders, pernicious anemia and vitiligo is well established and alopecia areata itself is conventionally regarded as an autoimmune disease (4). The importance of immune-mediated mechanism, but non necessarily autoimmunity, in the pathogenesis of alopecia areata is suggested by the therapeutic efficacy of immunosuppressive drugs such as cyclosporin A, tacrolimus and corticosteroids.
###end p 3
###begin p 4
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 595 596 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 343 348 <span type="species:ncbi:9606">human</span>
It is well known that locally infiltrating lymphocytes have been implicated as effector cells being responsible for the reversible alteration of the hair follicles and the resulting hair loss (5, 6). In general, the directional recruitment of leukocytes is regulated by chemokines and their counteracting chemokine receptors (7). Recently, in human models of AA it was shown that the increased expression of chemokines including monocyte chemoattractant protein-1 (MCP-1), monokine induced by interferon-gamma (MIG) might play a pivotal role in the attraction of monocytes around the hair bulb (1).
###end p 4
###begin p 5
###xml 376 377 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 378 380 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 443 448 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 588 593 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 853 855 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 857 859 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1020 1022 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1126 1128 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1237 1239 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 334 339 <span type="species:ncbi:9606">human</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
MCP-1 is a beta-chemokine that is thought to be responsible for monocyte and lymphocytes T recruitment in acute inflammatory conditions and may be an important mediator in chronic inflammation. In fact, it has been proposed that MCP-1 may be responsible for tissue inflammation in autoimmune diseases because its tissue expression in human and experimental autoimmune models (8-11). Thus, genetic polymorphism in the regulatory regions of the MCP-1 gene could be implicated in the susceptibility or progression of autoimmune disease. A biallelic A/G polymorphism at position -2518 of the MCP-1 gene has been described. The polymorphism proved functionally important, as peripheral blood mononuclear cells of individuals with G/G and A/G genotype produced significantly more MCP-1 after stimulation with IL-1beta than those with Caucasian wild-type A/A (12, 13). An association of the presence of G at position -2518 with the presence of cutaneous vasculitis could be shown in patients with systemic lupus erythematosus (14) as well as an association with development of coronary artery aneurysms after acute Kawasaki disease (13). Furthermore, the G/G genotype was identified as a genetic risk factor for severe coronary artery disease (15) and a correlation between the incidence and severity of asthma and the G allele at position -2518 has been shown. These findings suggest an important role for the MCP-1 and the A/G polymorphism in its regulatory region in inflammatory processes.
###end p 5
###begin p 6
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
The MCP-1 gene polymorphism in AA patients has not been reported yet. In this study, we performed a case-control study in 145 alopecia areata patients and 246 matched Korean controls to analyze the possible influence of the polymorphism (A/G) at position -2518 of the MCP-1 gene in the susceptibility of AA.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 8
###begin p 9
###xml 265 272 265 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 43 46 <span type="species:ncbi:9606">men</span>
###xml 54 59 <span type="species:ncbi:9606">women</span>
###xml 181 184 <span type="species:ncbi:9606">men</span>
###xml 193 198 <span type="species:ncbi:9606">women</span>
A total of 145 Korean patients with AA (70 men and 75 women) were examined at the Dermatology Clinic at the Kyung Hee University Medical Center. A total of 246 healthy subjects (80 men and 166 women), who had no clinical evidence of AA, were recruited as controls (Table 1). This study was approved by the ethics review committee of the Medical Research Institute, Kyung Hee University Medical Center.
###end p 9
###begin p 10
###xml 741 743 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 212 219 <span type="species:ncbi:9606">patient</span>
###xml 553 561 <span type="species:ncbi:9606">patients</span>
###xml 633 641 <span type="species:ncbi:9606">patients</span>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
###xml 1101 1109 <span type="species:ncbi:9606">patients</span>
###xml 1296 1304 <span type="species:ncbi:9606">patients</span>
The clinical diagnosis of AA was based on the presence of initially patchy alopecia with exclamation mark hairs and the exclusion of other causes of alopecia. Detailed clinical information was obtained from each patient, including age at onset of first episode, family history, type of disease (patchy alopecia, alopecia totalis [AT] and alopecia universalis [AU]), duration of disease, presence of other autoimmune disease, nail involvement, and other body sites hair loss. Clinical information was updated at follow-up examinations. We divided the AA patients into two subgroups according to disease severity. Subgroup 1 contained patients with patchy disease (patchy AA) and subgroup 2 patients with more extensive hair loss (AT and AU) (16). Patchy AA can involve the scalp or other body sites such as the beard area. In patchy AA (subgroup 1) there are well demarcated, mainly circular areas of hair loss typically 2-6 cm in diameter. In subgroup 2, hair loss progresses until all the hair on the scalp has been lost (AT); or to complete loss of the entire body hair (AU). We also divided the AA patients into two subgroups on the basis of age at onset of disease (17). The division of these subgroups with a boundary at age 30 yr was in keeping with the distribution of age at onset in our patients, which was bimodal with peaks at approximately age 20-30 and 30-40 yr.
###end p 10
###begin title 11
MCP-1 genotyping
###end title 11
###begin p 12
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pvu</italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 635 636 635 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 720 723 712 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
###xml 754 755 746 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1164 1167 1144 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pvu</italic>
###xml 1189 1190 1169 1170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Genomic DNA was prepared from heparinized venous blood samples using a NucleoSpin DNA isolation kit (MACHE-REY-NAGEL GmbH & Co., Duren, Germany). The identification of the polymorphism was carried out using PCR, followed by a restriction fragment length polymorphism (RFLP) assay, using a PvuII site, which is introduced by the presence of the G nucleotide. The regulatory region of the MCP-1 gene (from -2746 at -1817) was amplified by polymerase chain-reaction (PCR) using the forward primer 5'CCGAGATGTTCCCAGCACAG3'and the reverse primer 5'CTGCTTTGCTTGTGCCTCTT3'. PCR was performed using buffer 10x (10 mM Tris-HCl pH 9, 2.0 mM MgCl2, 50 mM KCl), 200 microm dNTPs, 2.5 pmoles of each primer, 0.5 microL of DNA, 0.5 U Taq polymerase (Pharmacia) and ddH2O up to a final volume of 10 microL. The following thermal profiles were run: 94℃ for 1 min, 55℃ for 1 min, and 72℃ for 1.5 min. After a final extension of 10 min at 72℃, 7 microL of the PCR products were resolved in 2% agarose gels stained with ethidium bromide previous dilution in blue juice buffer to check the expected 930-bp band. After checking, 8 microL of the PCR products were digested with 10 U of PvuII in 10x buffer and H2O up to a final volume of 20 microL at 37℃ for 2 hr 30 min.
###end p 12
###begin p 13
The resulting products were separated by gel-electrophoresis in 1.5% agarose gels, containing ethidium bromide in a final concentration of 0.5 microg/mL. Samples showing only a 930 bp band were assigned as A/A, samples showing two bands of 708 and 222 bp were considered G/G and samples showing three bands at 930, 708 and 222 bp were typed A/G.
###end p 13
###begin title 14
Statistical analysis
###end title 14
###begin p 15
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 114 115 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 123 124 121 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
The distribution of the MCP-1 A/G genotypes for patients and control subjects were compared by the chi-square (chi2) test. p value less than 0.05 were considered as statistically significant.
###end p 15
###begin title 16
RESULTS
###end title 16
###begin p 17
###xml 151 158 151 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 586 587 586 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 623 624 623 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 863 870 863 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 910 911 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1027 1028 1027 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 577 584 <span type="species:ncbi:9606">patient</span>
###xml 740 747 <span type="species:ncbi:9606">patient</span>
###xml 1000 1008 <span type="species:ncbi:9606">patients</span>
In the case-control study, genotype distributions and allele frequencies of the MCP genetic marker in both AA and the control population was analyzed (Table 2). In the AA patients the frequency of the A and G alleles was 40.3 and 59.7%, respectively and the distribution of the A/A, A/G and G/G genotypes was 19.3, 42.1 and 38.6%, respectively. Amongst the controls the frequency of the A and G alleles was 39.8 and 60.2%, and the distribution of the A/A, A/G, G/G genotypes in the same group was 17.5, 44.7 and 37.8%, respectively. The observed genotype frequencies of the AA patient (p=0.129) and the control population (p=0.574) did not show significant difference predicted by the Hardy-Weinberg equation. When the observed control and patient genotype frequencies were compared with expected values using 3x2 contingency table in a standard chi-square test (Table 2), there was no significant difference (p=0.848). Also, there was no significant difference in the allele frequencies between the patients and the controls (p=0.889).
###end p 17
###begin p 18
###xml 441 449 439 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3A</xref>
###xml 451 452 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">B</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
We then divided the patients into two subgroups (subgroup 1 [patchy AA] and subgroup 2 [alopecia totalis and alopecia universalis]) according to disease severity and also into two further subgroups on age at onset of disease (subgroup a [onset age </=30] and subgroup b [onset age >30]). Comparison of the genotype distributions and the allele frequencies between each subgroup and the control population revealed no significant difference (Table 3A, B).
###end p 18
###begin title 19
DISCUSSION
###end title 19
###begin p 20
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 190 195 190 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 614 619 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 884 885 884 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 893 894 893 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 267 272 <span type="species:ncbi:9606">human</span>
###xml 644 652 <span type="species:ncbi:9606">patients</span>
###xml 846 854 <span type="species:ncbi:9606">patients</span>
Although MCP-1 has been proposed as the main chemokine responsible for initiating autoimmune tissue damage (8, 11, 18, 19), the association of polymorphisms in the regulatory regions of the MCP-1 gene with alopecia areata has not been studied until now. Recently, in human models of AA it was shown that the increased expression of MCP-1 might play a pivotal role in the attraction of monocytes around the hair bulb (1). In addition, the MCP-1 -2518G allele was found to increase the MCP-1 expression (12). Therefore, we initially hypothesized that the development of AA might have been related to G allele in the MCP-1 gene polymorphism in AA patients. The results of this study, however, did not support this assumption. In this case-control study, the genotype distribution and allelic frequencies showed no significant difference between the patients population and the controls (p=0.848, p=0.889, respectively).
###end p 20
###begin p 21
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 921 926 921 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 1343 1345 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1818 1819 1818 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 1861 1866 1861 1866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
###xml 1133 1141 <span type="species:ncbi:9606">patients</span>
There are several potential reasons why there was no association between the -2518A/G polymorphism and alopecia areata. It is noteworthy that there are considerable differences in the frequencies of these polymorphisms among the different races. Indeed, it is well known that ethnicity and population structure may strongly influence the role of genetic risk factors in chronic inflammatory diseases including various autoimmune diseases. The distribution of several gene variations may be greatly different between various countries, as well as among different area in the same countries. The dominance of the G-type allele in Koreans, which were observed in this present study, is contrasting to what has been reported from Caucasians and AfroAmericans, where the proportion of G allele was 29 and 22%, respectively (12). Such reversed ratio was also observed in Japanese (13), suggesting that the genotypic profile of MCP-1 -2518 polymorphism varies greatly among ethnic groups. And, the -2518A/G polymorphism may not be associated with alopecia areata. Previously, it was shown that allelic frequency of -2518 polymorphism among patients with other autoimmune diseases with increased serum MCP-1 level, such as rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease, is also similar to that of normal controls (20). In addition, in study about the chemokine expression pattern of AA, Benoit et al. have demonstrated that MCP-1 expression does not appear to be a particular feature of AA due to showing MCP-1 expression by keratinocytes of the inner root sheath but only weak expression around the hair follicles. And chemokine expression patterns did not appear to correlate with clinical severity such as extent of hair loss, number of AA episodes, or presence of associated diseases (1). These findings argue against a role of MCP-1 -2518A/G polymorphism for susceptibility to alopecia areata.
###end p 21
###begin p 22
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
In conclusion, this study found no association of -2518A/G polymorphism in the distal regulatory region of the MCP-1 with alopecia areata susceptibility or severity in a Korean population. However, it is noteworthy that there are considerable differences in the frequencies of these polymorphisms among the different races. This variation may contribute to the pathogenesis of alopecia areata and must be considered in gene-association studies in different ethnic populations.
###end p 22
###begin article-title 23
Selective expression of chemokine monokine induced by interferon-gamma in alopecia areata
###end article-title 23
###begin article-title 24
###xml 34 39 <span type="species:ncbi:9606">human</span>
Structure and polymorphism of the human gene for the interferon-induced p78 protein (MX1): evidence of association with alopecia areata in the Down syndrome region
###end article-title 24
###begin article-title 25
A clinical study on alopecia areata (1996-2000)
###end article-title 25
###begin article-title 26
Role of the autoimmune regulator (AIRE) gene in alopecia areata: strong association of a potentially functional AIRE polymorphism with alopecia universalis
###end article-title 26
###begin article-title 27
Alopecia areata
###end article-title 27
###begin article-title 28
Alopecia areata-Animal models
###end article-title 28
###begin article-title 29
Chemokines and leukocyte traffic
###end article-title 29
###begin article-title 30
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis
###end article-title 30
###begin article-title 31
###xml 80 85 <span type="species:ncbi:9606">human</span>
Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis
###end article-title 31
###begin article-title 32
Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium
###end article-title 32
###begin article-title 33
Expression of MCP-1 in Kawasaki disease: the anti-inflammatory effect of gamma globulin-therapy
###end article-title 33
###begin article-title 34
A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression
###end article-title 34
###begin article-title 35
###xml 138 146 <span type="species:ncbi:9606">patients</span>
Monocyte chemoattractant protein-1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein-1 in Japanese patients with Kawasaki disease
###end article-title 35
###begin article-title 36
###xml 39 47 <span type="species:ncbi:9606">patients</span>
MCP-1 promotor polymorphism in Spanish patients with systemic lupus erythematosus
###end article-title 36
###begin article-title 37
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp (a) and MCP-1 -518 G/G genotype in CAD patients
###end article-title 37
###begin article-title 38
Heritable factors distinguish two types of alopecia areata
###end article-title 38
###begin article-title 39
HLA class II antigen association help to define two types of alopecia areata
###end article-title 39
###begin article-title 40
###xml 118 121 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</sup>
Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas lprmice
###end article-title 40
###begin article-title 41
###xml 79 83 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Renal expression of the monocyte chemoattractant protein-1 in lupus autoimmune mice
###end article-title 41
###begin article-title 42
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease
###end article-title 42
###begin p 43
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the 145 Korean alopecia areata patients and healthy controls
###end p 43
###begin p 44
AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis.
###end p 44
###begin p 45
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCP-1</italic>
Distribution of alleles and genotypes for the A/G SNP in MCP-1 in alopecia areata and control population
###end p 45
###begin p 46
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 65 71 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 147 160 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
*Observed vs. expected according to the Hardy-Weinberg equation, daggerControls vs. patients using the chi-square test with 2x2 contingency table, double daggerControls vs. patients using the chi-square test with 3x2 contingency table.
###end p 46
###begin p 47
Comparison of genotype distributions between each subgroup and the control population
###end p 47
###begin p 48
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
*Controls vs. patients using the chi-square test with 3x2 contingency table.
###end p 48
###begin p 49
Comparison of allele frequencies between each subgroup and the control population
###end p 49
###begin p 50
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
*Controls vs. patients using the chi-square test with 2x2 contingency table.
###end p 50

